Nivolumab combined with visugromab demonstrates enhanced efficacy and tolerability in treating muscle-invasive bladder cancer, outperforming placebo in a recent trial.
Paige Britt
Paige Britt is an assistant editor for Targeted Oncology.
Articles by Paige Britt
A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.
Camizestrant shows promising antitumor activity and tolerability when combined with CDK4/6 inhibitors in patients with advanced ER+, HER2– breast cancer.
Sevabertinib demonstrates promising safety and efficacy in treating non-small cell lung cancer with HER2 or EGFR mutations, offering hope for patients.
New research reveals that CD26+ leukemia stem cell levels at diagnosis predict treatment response in chronic myeloid leukemia patients, enhancing TKI therapy strategies.
XmAb819 shows promising antitumor activity and safety in advanced clear cell renal cell carcinoma, paving the way for future clinical advancements.
Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.
A phase 1 trial shows IO-202 combined with azacitidine effectively treats relapsed/refractory monocytic leukemias, demonstrating promising response rates.
Exosome-based therapy for glioblastoma receives FDA orphan drug designation, promising targeted treatment and improved delivery methods for cancer care.
AI transforms cancer treatment by personalizing care and enhancing patient-provider communication, revolutionizing how patients manage their health.
Experts discuss the impact of dose escalation in treating neuroendocrine tumors, highlighting recent trials and collaborative research efforts for improved patient outcomes.
A recent trial shows omacetaxine and venetoclax combination benefits patients with MDS but not AML, highlighting the need for further research.
Nirogacestat shows significant long-term benefits in treating desmoid tumors, improving survival rates and patient outcomes with manageable side effects.
The COMPETE trial reveals ITM-11 significantly improves progression-free and overall survival in patients with gastroenteropancreatic neuroendocrine tumors.
Zenocutuzumab gains FDA breakthrough therapy designation for advanced cholangiocarcinoma, showcasing promising trial results and potential targeted treatment options.
A clinical trial reveals no survival benefit from stem cell transplantation in lower-risk MDS patients, highlighting the need for improved posttransplant outcomes.
The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes and improving patient outcomes.
A phase 1 trial reveals camu camu's safety and potential benefits in melanoma and NSCLC patients undergoing immune checkpoint therapy.
Phase 2 trial CALYPSO reveals no improvement in outcomes for advanced renal cell carcinoma with savolitinib addition, prompting reevaluation of treatment strategies.
A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.
Triplet therapy of ciforadenant, nivolumab, and ipilimumab shows safety but lacks efficacy in advanced clear cell kidney cancer.
New trial results reveal that combining pembrolizumab and enfortumab vedotin significantly enhances survival rates in muscle-invasive bladder cancer patients.
Expert Joe DePinto analyzes the 2025 Cell and Gene Therapy Report, highlighting industry barriers and the growing role of oncologists in patient access.
Sunvozertinib shows promising efficacy and safety in treating advanced NSCLC with EGFR exon 20 mutations, paving the way for future research.
The COMPETE trial reveals ITM-11 significantly improves progression-free survival and overall response rates in GEP-NET patients compared with everolimus.
Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.
A new study shows mRNA-4359 combined with pembrolizumab offers promising results for melanoma patients resistant to prior therapies.
Tagraxofusp shows manageable safety but limited efficacy in chronic myelomonocytic leukemia (CMML), with ongoing studies exploring combination therapies for better outcomes.
Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a pivotal phase 3 trial.